Bone Regeneration Using PRF After Cyst Enucleation
Clinical Efficacy of Platelet-Rich Fibrin in Osseous Regeneration After Cystic Enucleation
Sana'a University
20 participants
May 19, 2025
INTERVENTIONAL
Conditions
Summary
This randomized controlled clinical trial aims to evaluate the clinical efficacy of autologous platelet-rich fibrin (PRF) in promoting osseous regeneration following cystic enucleation in the jaws. The study will assess bone healing outcomes and compare PRF application with conventional management methods.
Eligibility
Inclusion Criteria5
- Patients diagnosed with odontogenic cysts requiring surgical enucleation.
- Presence of a postoperative osseous defect in the jaws after cyst enucleation.
- Age ≥ 18 years.
- Systemically healthy patients (ASA I or II).
- Patients willing to participate and sign informed consent.
Exclusion Criteria6
- Patients with systemic diseases affecting bone healing (e.g., uncontrolled diabetes, osteoporosis).
- Patients receiving bisphosphonates or long-term corticosteroid therapy.
- Smokers (>10 cigarettes/day).
- Pregnant or lactating women.
- Patients with acute infection at the surgical site.
- Patients unwilling to participate or unable to attend follow-up visits.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Autologous platelet-rich fibrin (PRF) prepared from the participant's own venous blood will be placed into the osseous defect immediately after cystic enucleation. PRF will be prepared using standard centrifugation protocols and applied to promote bone regeneration.
Conventional cystic enucleation will be performed without the use of platelet-rich fibrin (PRF). The osseous defect will be managed according to standard surgical protocol and allowed to heal naturally.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07424716